spacer
home > ebr > summer 2017 > revolution or evolution?
PUBLICATIONS
European Biopharmaceutical Review

Revolution or Evolution?

Over the last 5-10 years, the biopharmaceutical industry predicted that the development of biosimilars would revolutionise the field of biologics by offering low-cost alternatives for many of these innovative therapies across multiple therapeutic areas. For example, when the Biologics Price Competition and Innovation Act was signed into law in the US as a subsection of the Affordable Care Act in 2010, it was accompanied by expectations of significant cost savings for both patients and the healthcare system. The expected savings over 10-15 years ranged from $25 billion to $250 billion, as put forth by the Congressional Budget Office and Express Scripts respectively (1).

The reality, however, is that the biosimilars market has developed much slower than expected Ė today, there are only three biosimilars approved in the US and 22 in the EU. To compete in the marketplace, biosimilars must be manufactured more efficiently to realise competitive pricing compared to their off-patent reference biologic. Developing these therapies is extremely challenging because they are required to have the same structure, activity and clinical efficacy and safety profile as the reference biologic, which adds significant complexity to the process.

Moreover, as the competition increases among biosimilars targeting the same reference biologic, companies are under further pressure to attain lower costs and maximise manufacturing flexibility. The high expenses associated with development therefore pose a significant hurdle for biosimilars manufacturers, who must compete on price.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Guillaume Plane is the Global Development and Marketing Manager for Merck's Biodevelopment Services. He joined the company in 2012, bringing over 15 years of biotechnology experience spanning multiple specialities. Guillaume also serves as Visiting Professor at ESCP Europe, Toulouse Business School and IONIS School of Technology and Management. He received a masterís degree in biology and health from the University of Bordeaux, France, and an additional masterís degree in innovation and entrepreneurship from ESCP Europe. 
spacer
Guillaume Plane
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

YHEC announced appointment of Stuart Mealing as Associate Director of Health Technology Assessment

YHEC is pleased to announce the appointment of Stuart Mealing as Associate Director of Health Technology Assessment. Stuart will be leading the YHEC economic evaluation and modelling team. Stuart has a Masterís degree in operational research from the University of Lancaster Business School and a post-graduate certificate in international business management from Smurfit Business School, Dublin.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 
Industry Events

LogiMed 2017

18-19 October 2017, Hyperion Hotel, Hamburg

Taking place 18-19th October in Hamburg, LogiMed is Europeís only dedicated medical device supply chain event bringing together over 150 Medical Device Supply Chain Professionals to network with. With a greater focus on customer collaboration and digital transformation this yearís LogiMed delivers real insights on inventory visibility, supply chain planning, global logistics and digitalization.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement